FDA Approves ILUMYA for Active Psoriatic Arthritis in Adults
FDA approves Sun Pharma's ILUMYA (tildrakizumab) for active psoriatic arthritis in adults, supported by Phase 3 INSPIRE-1 and INSPIRE-2 data at 24 weeks.
Topic
Ilumya
Topic
Topic
Topic
FDA approves Sun Pharma's ILUMYA (tildrakizumab) for active psoriatic arthritis in adults, supported by Phase 3 INSPIRE-1 and INSPIRE-2 data at 24 weeks.